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1. Introduction 
The current approach to the diagnosis and treatment of hyponatremia is in a state of flux, 
largely because of an unresolved controversy regarding the relative prevalence of the 
syndrome of inappropriate secretion of antidiuretic hormone (SIADH) and cerebral salt 
wasting, or preferably renal salt wasting (RSW). The recent awareness that symptoms are 
now being attributed to even mild hyponatremia has led to recommendations to treat 
virtually all hyponatremics. (Arief et al, 1976; Berl et al, 2010; Decaux, 2006, 2009; Gankam 
Kegne et al, 2008; Hoorn et al, 2009; Renneboog et al, 2006; Sterns et al,2009; Schrier, 2010)   
This tendency to treat even mild hyponatremia introduces an urgency to resolve the 
diagnostic dilemma of differentiating two syndromes, SIADH and RSW, with divergent 
therapeutic goals, to water-restrict in SIADH or administer salt and water in RSW. We 
propose to define RSW by supporting data and review the pathophysiology of RSW, the 
derivation and evolution of the controversy over the relative prevalence of SIADH and 
RSW, and methods to differentiate SIADH from RSW. We will also review the emerging 
value of determining fractional excretion (FE) of urate in the evaluation of patients with 
hyponatremia by emphasizing our recent observations in reset osmostat, identify conditions 
that predispose to RSW, amplify the possibility that RSW might exist in patients with an 
increased FEurate without hyponatremia and propose an algorithm where FEurate is central 
to the evaluation of hyponatremia. We will also advocate and hopefully justify changing the 
designation, cerebral salt wasting, to renal salt wasting, and briefly discuss different 
strategies to treat hyponatremia. 
2. Definition of RSW 
In our view, RSW is most accurately defined as, “extracellular volume (ECV) depletion due 
to a renal sodium transport abnormality with or without high urinary sodium concentration 
(UNa), presence of hyponatremia or cerebral disease and normal renal, adrenal and thyroid 
function”. (Maesaka et al, 2009) We will provide data to support our contention that UNa 
can be low in RSW, and how RSW can occur in normonatremic patients and in patients 
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without cerebral disease. Although an increased FEurate has been demonstrated in a 
number of patients with RSW, we will withhold including FEurate to our definition of RSW 
until there are more confirmatory data.    
2.1 Pathophysiology of RSW 
RSW starts with a disease entity that appears to induce production of a natriuretic factor(s) 
that inhibits mainly proximal tubule sodium transport and possibly other solutes such as 
urate. Depending on the balance between the severity of the sodium transport defect and 
sodium intake, ECV depletion of varying magnitude ensues. The patient will first enter a 
stage of negative sodium balance, which will stimulate the renin-angiotensin aldosterone 
system, reduce atrial/brain natriuretic peptide (A/BNP), alter glomerular hemodynamics 
and possibly activate neural factors that attempt to decrease sodium excretion. (Abuelo, 
2007)  In some, a combination of inadequate sodium intake and profound inhibition of 
tubule sodium transport can lead to severe, symptomatic ECV depletion that is manifested 
as postural hypotension, unsteady gait, and postural somnolence, dizziness and slurred 
speech. (Gutierrez et al, 2007; Maesaka et al, 1990, 2007; Wijdicks et al, 1985)  A more 
common scenario is a milder defect in sodium transport and mild ECV depletion that cannot 
be appreciated unless we refine our ability to diagnose RSW accurately. There are, therefore, 
different degrees of volume depletion that depend on the severity of the inhibition of renal 
sodium transport and salt and water intake. The true prevalence of RSW, therefore, cannot 
be appreciated until we refine methods of determining ECV accurately by simple methods 
or develop other as yet unidentified methods of defining RSW. Moreover, because SIADH 
and RSW typically present with hyponatremia, high urine osmolality and UNa, these 
overlapping features of RSW and SIADH and divergent therapeutic goals of each syndrome 
introduce an urgency to differentiate one syndrome from the other to achieve these 
opposing therapeutic goals.  
The volume-depleted subject must reach an equilibrated state of sodium balance, otherwise 
a sustained negative sodium balance will result in total loss of body sodium and collapse of 
the vascular system. Sodium excretion and UNa can thus be low, if sodium intake is low. 
(Maesaka et al, 2007) A similar sequence of negative sodium balance followed by 
equilibration has been noted for SIADH. (Jaenike et al, 1961) The increase in water 
reabsorption maintains ECV at high normal and increases ANP levels, which can cause 
natriuresis by multiple factors. (de Zeeuw et al, 1992)   
Interestingly, plasma renin in RSW can be variable depending on sodium intake, whereas 
plasma aldosterone tends to be increased irrespective of sodium intake when volume 
depleted. (Bitew et al, 2009; Maesaka et al, 2007)  In this scenario, we noted increased plasma 
renin in a patient with RSW while on a low sodium intake. The decrease in sodium delivery 
to the distal tubule stimulated COX2 activity and increased plasma renin. (Traynor et al, 
1999) On the other hand, a salt wasting patient on a normal sodium intake had higher 
sodium delivery to the distal tubule by virtue of an underlying decrease in proximal tubule 
sodium transport that failed to increase COX2 activity and maintained normal plasma renin, 
while being volume depleted. (Bitew et al, 2009; Traynor et al, 1999) 
In contrast to SIADH, when ADH production fails to respond to conventional volume and 
osmolar stimuli, there is appropriate stimulation of ADH production in RSW by ECV 
depletion. The volume stimulus for ADH production is more potent than the osmolar effect 
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on ADH production, so a volume depleted patient continues to increase ADH production, 
increase free water reabsorption and decrease serum sodium and osmolality. (Robertson & 
Ganguly, 1986)  Administration of saline in our patient with RSW eliminated the volume 
stimulus for ADH production to allow the coexisting hypoosmolality of plasma to inhibit 
ADH production to indeterminate levels, thus decreasing urine osmolality, increase free 
water excretion and increase serum sodium, figure 1.  
 
Fig. 1. Urine osmolality and serum sodium concentration during saline infusion at 125 
ml/hr. over 48 hour period. Note dilution of urine 13 hours after initiation of saline, at 
which time a previously increased plasma ADH was not detectable, appropriate AD 
secretion. See text. (reproduced with permission from publisher)  
This appropriate increase in plasma ADH in a patient with unequivocal RSW illustrates this 
important physiologic difference between RSW and SIADH. (Maesaka et al, 2007, 2009)  As 
noted earlier, the task of clinically determining whether the increase in plasma ADH levels 
are appropriate or inappropriate rests solely on differences in ECV, since both present with 
hyponatremia, high urine osmolality and UNa. Our reliance on the assessment of ECV 
becomes critical in differentiating SIADH from RSW. Our inability to assess this critical 
parameter remains central to the unresolved controversy regarding the prevalence of 
SIADH and RSW. (Maesaka et al, 2009, 1999; Oh & Carroll, 1999; Singh et al, 2002).          
2.2 Natriuretic factor(s) in RSW 
Atrial or brain natriuretic peptide (A/BNP) has been frequently mentioned as a possible 
cause of the salt wasting in RSW. (Ellison & Berl, 2007; Palmer, 2003)  A/BNP has been 
reported to be increased in patients with subarachnoid hemorrhage (SAH), a condition that 
has been shown to have a high prevalence for RSW, but it has also been reported to be 
increased in a non salt wasting syndrome such as SIADH and salt-retaining conditions such 
as congestive heart failure. (Burnett et al, 1986; Fichman et al, 1974; Wijdicks et al, 1991) The 
low normal ANP level in RSW is consistent with the volume-depleted state and strongly 
argues against any role of ANP in salt wasting. (Maesaka et al, 2007, Vogel, 1963)   
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ANP increases GFR, decreases renal blood flow and blood pressure and increases sodium 
excretion by the increase in GFR and inhibition of sodium transport in the proximal and 
distal tubule. ANP responds to changes in intravascular volume and would be lower in 
volume depleted states such as RSW. (Maesaka et al, 2007)  The contribution of ANP in 
maintaining sodium homeostasis has not been clearly established, being considered by some 
to have no role as compared to others who feel ANP does contribute to sodium balance. (de 
Zeeuw et al, 1992).  
The infusion of BNP into normal subjects increased GFR, decreased renal plasma flow, 
increased urine flow and sodium excretion, and inhibited plasma renin without affecting 
blood pressure, angiotensin II or aldosterone levels. There was evidence for inhibition of 
proximal tubule and larger inhibition of distal sodium transport. (Jensen, 1998) There is 
questionable relevance of these findings to RSW because A/BNP responds to changes in 
intravascular volume and are, thus, lower in RSW. (Maesaka et al, 2007; Vogel, 1963) We 
favor a natriuretic factor that does not have characteristics of A/BNP that is evident in 
plasma and urine of patients with evidence for RSW, see below.  
We infused plasma from patients with neurosurgical and Alzheimer’s diseases (AD) with 
increased FEurate and normonatremia into rats, and demonstrated a significant increase in 
FElithium and FENa, suggesting that a natriuretic factor(s) had a predominant effect on 
proximal tubule sodium transport. (Maesaka et al, 1993, 1993) Blood pressure and GFR 
remained unchanged from baseline and from controls throughout the study. Since lithium 
transport follows sodium transport on a one to one basis in the proximal tubule in the 
absence of nonelectrolyte solutes such as mannitol, the significant increase in FElithium 
from 22.3 and 27.2% in control animals to 36.6 and 41.7% in neurosurgical and AD patients, 
respectively, indicates that the same fraction of filtered sodium escaped reabsorption in the 
proximal tubule. (Dorhout Mees,1990; Leyssac et al, 1990; Maesaka et al 1993, 1993) This 
increase in distal delivery of sodium only increased FENa significantly from control values 
of 0.3 and 0.33% to 0.59 and 0.63% in rats infused with plasma of neurosurgical and AD, 
respectively, indicating that the distal tubule had actually increased distal sodium 
reabsorption from control values of 22.0 and 26.87% to 36.01 and 41.07% of the filtered 
sodium. (Maesaka et al, 1993, 1993)  The significant increase in FENa indicated a net sodium 
loss in animals infused with plasma of neurosurgical and AD. An unresolved question is 
whether the increase in the distal delivery of sodium exceeded the capacity of the distal 
tubule to transport sodium or whether the natriuretic factor(s) had an effect on distal 
sodium transport as well. These data, nevertheless, indicate that the major site of natriuretic 
activity resides in the proximal tubule and there was a net loss of sodium. In RSW the 
increase in FEurate, an anion that is exclusively transported in the proximal tubule, supports 
our proposal that the major site of solute transport abnormality in RSW is in the proximal 
tubule and introduces the possibility that the natriuretic factor(s) might affect more than one 
transporter. (Maesaka & Fishbane, 1998) Moreover, these data do not have any similarities 
to the effects of A/BNP.  
More recently, ammonium precipitates of urinary proteins of 5 of 6 neurosurgical patients 
with increased FEurate and normonatremia inhibited transcellular 22Na transport in a dose-
dependent manner across cultured pig proximal tubule cells, LLC-PK1, in transwells, as 
compared to precipitates from urine of neurosurgical patients with normal FEurate and 
normonatremia, and SIADH. (Youmans & Maesaka, 2011) These data support our previous 
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studies in neurosurgical and AD, who had increased FEurate with normonatremia, an 
association that is highly suggestive of RSW. This conclusion is consistent with the 
frequency with which RSW is seen in neurosurgical diseases, with and without 
hyponatremia, see below. (Nelson et al, 1981; Sivakumar et al, 1994; Singh et al, 2002; 
Wijdicks et al, 1985)  
3. Controversy over the relative prevalence of RSW and SIADH 
The consistent view among internists and nephrologists is that RSW is a rare entity as 
compared to neurosurgeons, who consider RSW to be a common disorder. This important 
controversy exists because of the difficulty with which one syndrome can be differentiated 
from the other by usual clinical criteria. Because of overlapping clinical parameters such as 
hyponatremia, concentrated urines with high UNa, hypouricemia, increased FEurate, 
associations with intracranial diseases and normal renal, thyroid and adrenal function, there 
is a diagnostic dilemma that must be resolved in order to arrive at an appropriate 
therapeutic strategy for both syndromes. The only difference on first exposure with the 
patient is the volume depletion in RSW and increased volume in SIADH. (Bitew et al, 2009; 
Schwartz et al, 1957)  Unfortunately, the clinical assessment of the volume status of non-
edematous patients has been regarded as consistently inaccurate by usual clinical criteria. 
(Chung et al, 1987; Maesaka et al, 1999; Oh & Carroll; 1999; Singh et al, 2002)  
We and others have encountered patients with RSW, who became symptomatic while being 
water-restricted for an erroneous diagnosis of SIADH. (Gutierrez et al ,2007; Maesaka et al, 
1990,2007; Wijdicks et al, 1985 ) The common teaching that RSW is a rare clinical entity 
virtually eliminates its consideration when encountering patients with nonedematous 
hyponatremia. Because the major diagnostic conundrum rests with the volume status of 
these patients, we will review volume studies, mainly in neurosurgical patients, and offer 
strategies by which we can differentiate one syndrome from the other. In our view, the 
myriad of studies that have been published on cerebral/renal salt wasting, including the 
original report on cerebral salt wasting, has not adequately supported the diagnosis of RSW 
and have contributed to misconceptions. We will attempt to identify parameters by which 
the diagnosis of RSW can be made in order of their priority. We hope this review will 
provide information that will allow the reader to assess critically the merit of manuscripts 
on RSW and SIADH. 
4. Evolution of the controversy over the existence and prevalence of RSW 
The derivation of the controversy regarding the existence and relative prevalence of RSW 
and SIADH can be appreciated by a brief review of salt balance in normal subjects. Studies 
in Yanomamo Indians, the “no salt society”, support the notion that we require virtually no 
salt in our diet to maintain normal ECV. (Hollenberg, 1980; Oliver et al, 1975)  In Yanomamo 
Indians, the mean sodium excretion is 1 mmol/day, mean serum sodium 140 mmol/L, 
mean urine volume 1 L/day and mean blood pressure 102/62 mmHg. (Oliver et al, 1975)  
These studies suggest that we require little or no salt in our diets to maintain normal ECV.   
Normal kidneys appear to have an innate sense of what is a normal ECV for that individual 
and adjust to any fluctuations in sodium intake to maintain ECV within narrow limits. 
(Hollenberg, 1980) The adjustments, however, are not instantaneous as sodium excretion 
will exceed input for up to 5 days before reaching equilibrium after an acute reduction in 
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sodium intake. (Valtin, 1997)  When a normal subject is placed in negative sodium balance 
by increasing urinary sodium excretion by diuretics or increased sweating, urinary sodium 
excretion decreases to as low as 1 mmol/day. (McCance, 1936; Strauss et al, 1958) Sodium 
excretion does not increase until the sodium losses have been replenished. (McCance, 1936; 
Strauss et al, 1958) This important role of normal kidneys to conserve sodium, when in a 
state of negative sodium balance is, in retrospect, the basis for the birth of the term cerebral 
salt wasting syndrome in 1950. (Peters et al, 1950) Peters et al reported 3 subjects with 
cerebral disease, acute encephalitis, subarachnoid hemorrhage and bulbar poliomyelitis. 
They concluded unconvincingly that these patients presented evidence of salt wasting, 
which was characterized by nitrogen retention, low blood pressure and correction of their 
hyponatremia by large salt intake. Nitrogen retention occurs in a volume depleted patient, 
referred to as prerenal azotemia, with retention of urea or nonprotein nitrogen (NPN), 
approximately double the BUN. (Abuelo, 2007) This is a reasonable assumption because 
urea excretion increases with any increase in urine output, even in RSW during volume 
repletion. (Shannon, 1936) NPN decreased from a baseline 44 to 25 mg/dL after receiving 
large amounts of salt in the first case.  Only one NPN determination was reported in the 
second case with SAH and none was reported in the third case with bulbar poliomyelitis. 
The blood pressure in the first patient was 110/70 mmHg when the NPN was 44 mg/dL 
with preceding blood pressures of 120/80 to 130/88 mmHg without testing for postural 
changes in blood pressure or pulse. The second patient with SAH had one blood pressure 
reading of 220/110 mmHg and none was reported for the third case. The hyponatremia in 
all 3 patients did not respond to long periods of increased salt intake. The salt balance study 
that lasted 39 hours revealed the patient to be in negative sodium balance after salt intake 
was acutely reduced from 15 g/day to no salt intake. This delay in reaching equilibrium on 
the third day after an acute reduction in salt intake was construed as salt wasting, but is 
actually consistent with observations made in normal subjects. (Valtin, 1997) The negative 
sodium balance for 39 hours after an acute reduction in sodium intake does not justify the 
diagnosis of salt wasting. The first “dehydrated”case, however, could have had salt wasting. 
McCance and Strauss et al reported that a volume depleted subjects would avidly conserve 
sodium until their sodium losses were replaced. (McCance, 1936; Strauss et al, 1958) This 
“dehydrated” or assumed volume depleted patient had a urine chloride of 61.6 mmol/L, 
which can be explained by RSW. The inability to assess clinically the state of ECV has been 
the basis for doubting the existence of RSW. The same shortcomings were repeated in 
another report by the same authors on salt wasting. (Welt et al, 1952)  
Four years later, Cort reported a hyponatremic patient with astrocytoma and papilledema, 
who had signs of dehydration. (Cort, 1954) Sodium intake of 15 g/day for many days failed 
to correct the hyponatremia. In a nine-day balance study, sodium intake was acutely 
reduced to 142.5 mg/day. The patient received corticotrophin on days 4, 5 and 6, 
deoxycorone on days 7, 8 and 9 and restarted on 15 mg/day salt on day 10.  The patient 
went into negative sodium balance of 100 mmol on the first day and 60-70 mmol/day for the 
next 8 days. Sodium balance was unaffected by corticotrophin or deoxycortone. This study 
was compared to a similar study by McCance, who found normal subjects to go into sodium 
balance by the 5th day. (Cort, 1954) Determinations of daily chloride space revealed a 1.4 L 
reduction on the first day and 690 ml on the 9th day. Resumption of 15 g/day salt intake 
increased the chloride space by 1 L and her serum sodium “restored toward normal”. (Cort, 
1954) The reduction in chloride space and prolonged negative sodium balance prove the 
existence of RSW.  
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In 1957 Schwartz et al published their seminal report on SIADH that captured the fancy of 
physiologists and clinicians by reproducing the data in studies of vasopressin injections in 
healthy subjects by Leaf et al to propose the inappropriate secretion of ADH without the 
benefit of measuring plasma ADH levels. (Leaf et al, 1953; Schwartz et al, 1957) They proved 
convincingly that a hyponatremic patient, who presents with a concentrated urine, high 
UNa and increased ECV, as determined by radiosulfate measurements of ECV, must be due 
to an inappropriate secretion of ADH. ADH did not respond to the usual volume or osmolar 
stimuli and thus termed it inappropriate. The hyponatremia that was associated with a high 
UNa of 70 mmol/L and euvolemia or hypervolemia strengthened by determination of 
radiosulfate space, defined a syndrome that was not consistent with cerebral or renal salt 
wasting. (Schwartz et al, 1957)    
There are several characteristics of SIADH that are worth reviewing as they relate to 
hyponatremia. These patients go into a period of negative sodium balance followed by an 
equilibrated state when sodium intake matches output. (Janenike & Waterhouse,1961) There 
is an increased blood volume as determined by sulfate space and by radioiodinated serum 
albumin and 51Cr labeled red blood cells. (Bitew et al, 2009; Schwartz et al, 1957)                          
The hypervolemia reduces plasma renin and aldosterone and increase plasma A/BNP. 
(Bitew et al, 2009; Fichman et al, 1974) GFR increases and urine osmolality is invariably 
concentrated. (Beck, 1979)  Urine osmolality can, however, be dilute under circumstances of 
“ADH escape”. Dilute urines have been noted after rapid infusion of saline at 2 L over a 2 hr 
period and after reducing sodium intake. (Jaenike & Waterhouse, 1961; Schwartz et al, 1957) 
Several possible explanations for this interesting phenomenon include a down regulation of 
V2 receptor or increased urine flow rates cannot equilibrate with the hypertonic medulla. 
(Hoorn et al, 2005)  
An unappreciated observation is an increase in serum sodium despite high fluid intake in 
SIADH. A balance study reported an increase in serum sodium from 105 to 135mmol/L 
over an 8 day period, when the mean fluid intake was 2648 ml/day and mean daily sodium 
intake of 315 mmol/day. The mean sodium concentration of 124.4 mmol/L in the input 
fluid was higher than the mean UNa of 86.8 mmol/l over the 8 day period. The sodium 
concentration in the intake fluid exceeded UNa on every day of the study, suggesting that 
serum sodium can increase even in SIADH as long as sodium concentration in the intake 
fluid exceeds UNa, regardless of the intake volume. (Schwartz et al, 1957) This reasoning 
can be applied to desalination when saline infusion decreases serum sodium. (Steele et 
al,1997). In the first case of SIADH, serum sodium decreased from 121 to 114 mmol/L after 
saline infusion when UNa was 70 mmol/L and to 103 mmol/L after hypertonic saline 
before undergoing a metabolic study. It is unlikely that serum sodium decreased while 
receiving saline, with a sodium concentration of 155 mmol/L, when UNa was 70 mmol/L. 
This is not consistent with desalination. (Steele et al, 1997) The best explanation for this 
phenomenon is an unrecorded intake of water that decreased the input sodium 
concentration below UNa. (Schwartz et al, 1957)  
These elegantly designed studies in the initial report of SIADH proved that a hyponatremic 
patient can have high UNa without invoking RSW, largely because the volume status was 
shown to be increased by credible methods of determining ECV and not by tenuous clinical 
criteria as in the original report. (Peters et al, 1950) The existence of cerebral salt wasting was 
appropriately questioned. Since the assessment of ECV is critical in differentiating SIADH 
from RSW, it would be appropriate to review the various methods by which we assess ECV.  
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5. Assessment of extracellular volume 
It is generally agreed that the assessment of ECV by clinical criteria is fraught with 
inaccuracies that the term “appeared dehydrated” is not acceptable for clinical and research 
purposes. (Chung et al, 1987; Maesaka et al, 1999; Oh & Carroll, 1999; Singh et al, 2002)  The 
usual criteria of tissue turgor, axillary sweat, dry mucus membranes, neck vein distention or 
even postural hypotension in a nonedematous patient have been collectively inaccurate in 
assessing ECV. Even the presence of postural hypotension must consider autonomic 
dysfunction as we reported in a hyponatremic patient with autonomic failure and SIADH, 
proven by increased blood volume by gold standard radioisotope-dilution methods and 
depressed plasma renin and aldosterone. (Bitew et al, 2009)  The use of plasma renin and 
aldosterone to differentiate SIADH from RSW can be helpful under ideal circumstances. In 
SIADH, plasma renin and aldosterone levels should be depressed, reflecting a slightly 
hypervolemic state, while in RSW, both levels should be increased, reflecting volume 
depletion. Clinically, however, determinations of plasma renin and aldosterone are delayed. 
Their diagnostic value is limited by a variety of exogenous factors. They include medication 
like ACE inhibitors, ARBs, B-Blockers, NSAIDS, heparin, diuretics and hyperuricemia. 
(Mulatero et al, 2002; Eraranta et al, 2008) A/BNP has not been used to differentiate SIADH 
from RSW.   
It appears that noninvasive methods to assess ECV have limited value. Invasive methods 
have also been limited by various factors. A commonly used parameter is to measure central 
venous pressures (CVP). CVP has a poor correlation with concomitant radioisotope dilution 
measurements of blood volume and is also being discarded as a guide to fluid management. 
(Marik et al, 2008) The use of bioimpedance to determine volume in different compartments 
of the body is not useful as a single determination. (Schneditz, 2006)) Pulmonary wedge 
pressures are limited by a failure consistently to predict ECV but also by their invasiveness. 
(Godje et al, 1998) 
There are two credible methods that can reliably determine ECV with greater accuracy than 
methods discussed above. One is the gold standard radioisotope-dilution method, using 
radioiodinated serum albumin and/or 51Cr-tagged red blood cells, and the other, 
determination of total body water by deuterium and extracellular water by sodium 
bromide. As will be discussed below, there are a limited number of studies using 
radioisotope-dilution methods in SIADH and RSW and none using measurements of total 
and extracellular water in either of these two groups of patients.  
5.1 Volume studies using radioisotope-dilution and other pertinent methodologies 
As reviewed above, estimates of ECV have been made by determining chloride and 
thiosulfate spaces to support other criteria to establish the diagnosis of RSW and SIADH, 
respectively. (Cort, 1954; Schwartz et al, 1957) The gold standard for determining blood 
volume is by radioisotope dilution methods including radioiodinated serum albumin 
and/or 51Cr labeled red blood cells. A study of 12 neurosurgical hyponatremic patients with 
UNa ranging from 41-203 mmol/L had blood volume determined by 51Cr tagged red cells 
and radioiodinated serum albumin. Ten of the 12 patients had decreased blood volume and 
2 had increased blood volume as compared to 6 control patients. (Nelson et al, 1981) The 
high UNa of 41 to 203 mmol/L suggests that 83.3% had RSW and 16.7% had SIADH. Eight 
patients had subarachnoid hemorrhage (SAH). In another study, plasma volume was 
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determined by radioiodinated serum albumin in 21 patients on the first day of admission 
within 48 hours after SAH and on the 6th day after SAH. Comparisons between the first and 
second volume determination revealed blood volume to decrease in 8 of 9 hyponatremic 
patients, suggesting that 88.9% had RSW and 11.1% had SIADH. UNa values were not 
reported. (Wijdicks et al, 1985)  Interestingly, plasma volume was decreased in 8, 66.7%, and 
increased in 4, 33.3%, of 12 nonhyponatremic patients with SAH, suggesting that RSW can 
occur in nonhyponatremic patients. Moreover, all 8 hyponatremic and 8 of 12 
nonhyponatremic patients with decreased blood volume were in negative sodium balance. 
The increased blood volume in the 4 patients with normonatremia raises the question of 
whether or not SIADH can occur with normonatremia. In a separate study, Water restriction 
in volume depleted patients with SAH increased morbidity and mortality, probably due to 
decreased perfusion of brain and extension of ischemia in an already compromised 
circulation. (Wijdicks et al, 1985)  
Another study used 51Cr tagged red cells and CVP measurements in 18 hyponatremic 
patients of various etiologies with UNa of 43-210 mmol/L. (Sivakumar et al, 1994) 
Seventeen of 18 patients had decreased blood volumes, 18 of 18 patients had decreased CVP 
and all 18 patients corrected their hyponatremia within 72 hours after initiating saline 
infusion. The high UNa, decreased blood volume and correction of hyponatremia within 72 
hours after initiating saline therapy argue strongly for RSW. We demonstrated a similar 
correction of hyponatremia within 48 hours after initiation of saline therapy in two patients 
with RSW and failure of saline therapy to correct the hyponatremia in two patients with 
SIADH. (Bitew et al, 2009; Maesaka et al, 2007) The three neurosurgical studies demonstrate 
by acceptable methods of determining ECV, that RSW is much more common than SIADH 
in neurosurgical patients, especially SAH.  
A study in neurosurgical patients determined blood volume by 51Cr labeled red cells in 20 
hyponatremic and 20 nonhyponatremic “control” patients. Patients with evidence of 
“dehydration or hypovolemia” were excluded. All met criteria for SIADH. (Brimioulle et al, 
2008)  The exclusion of dehydrated or hypovolemic patients might have excluded patients 
with RSW and meeting the criteria for SIADH would include patients with RSW. Blood 
volumes were found to be comparable in the “control” and hyponatremic groups, 
suggesting that the hyponatremic group was entirely SIADH. Interestingly both the 
“control” and experimental groups were hypouricemic, mean serum urate 2.7 and 1.3 
mg/dL and had high mean FEurate of 19% and 32% (normal 5-10%), respectively. There is 
ample evidence to suggest that the high FEurate in the hyponatremic group was consistent 
with both SIADH and RSW, while the nonhyponatremic group with increased FEurate 
would be consistent with RSW or normal controls depending on whether the FEurate was 
high or normal, respectively, figures 3, 4, table 1. (Maesaka et al, 1996, 1998, 1999, 2009) 
Based on these diagnostic possibilities, this study suffers first from a protocol-based 
elimination of patients with evidence of volume depletion as in RSW and failure to select the 
proper “control” and hyponatremic groups. 
Ten patients with acquired immune deficiency syndrome with saline-responsive postural 
hypotension had CVP of 0 cm water, increased renin and aldosterone, hyponatremia, 
hypouricemia, elevated FEurate and UNa >40 mmol/l, which collectively support the 
diagnosis of RSW. (Cusano et al, 1990; Maesaka et al, 1990) 
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5.2 Other pertinent studies 
In a retrospective study of 319 patients with SAH, 179 were hyponatremic and met criteria 
for SIADH and CSW. They found that 69.2% had SIADH, 6.5% CSW and 4.8% a 
combination of SIADH and CSW. The volume status was determined by CVP 
measurements, presence of hypotension and undefined parameters. This report suffers by 
its retrospective design, paucity of data to support their diagnoses and reliance on CVP 
measurements that have little value in assessing ECV. (Sherlock et al, 2006)  In a similar 
retrospective study that included a variety of intracranial diseases, they found 62% of 
patients to have SIADH, 26.7% hypovolemic, 16.6% drug-related, 4.8% CSW, 3.7% related to 
IV fluids and 2.7% a combination of CSW and SIADH. In both studies, the combination of 
SIADH and CSW in 4.8% and 2.7% of patients lacked supportive data to justify such a 
difficult and improbable diagnostic combination, especially in a retrospective study. 
(Sherlock et al, 2006, 2009)  
6. Renal salt wasting without clinical evidence of cerebral disease      
To add further confusion to the dilemma of differentiating SIADH from RSW, we recently 
published 2 cases of unequivocal RSW without cerebral disease. (Bitew et al, 2009; Maesaka 
et al, 2007) One very instructive case was a hyponatremic patient with a hip fracture, who 
was initially water-restricted for 7 days for an erroneous diagnosis of SIADH by an internist. 
While being water-restricted, her Uosm was 362 mosm/kg and UNa only 6 mmol/L, which 
was initially construed as being consistent with hypovolemic hyponatremia of the prerenal 
type when UNa is typically low. A serum urate of 3.4 mg/dL, however, was not consistent 
with prerenal azotemia and more consistent with SIADH and RSW. A volume-depleted 
patient with normal kidney function would have higher serum urate with a FEurate below 
3%. (Steele, 1969) Based on this reasoning, we performed a blood volume determination by 
gold standard radioisotope dilution methods and started saline infusion after baseline 
studies were collected. As expected the FEurate was markedly elevated at 29.6%, which was 
consistent with both SIADH and RSW, but a 7.1% reduction in blood volume was consistent 
with RSW. Increased baseline plasma renin and aldosterone and low normal ANP strongly 
supported the diagnosis of RSW. The low UNa of 6 mmol/L was attributed to a loss of 
appetite and reduced salt intake while being fluid-restricted to 750 ml/day for 7 days prior 
to our studies. She was feeling weak and anorectic while being fluid-restricted and felt 
stronger with increased appetite approximately 18 hours after initiating saline infusion. The 
baseline Uosm of 362 mosm/kg was attributed to a low medullary solute concentration 
resulting from low salt intake. A Uosm of 587 mosm/kg in the first urine passed after 
initiation of saline infusion supports our contention that the low salt intake decreased 
medullary solute concentration and decreased concentrating ability of the kidney, figure 1. 
The UNa of 6 mmol/L reflects her low sodium intake and reduction of renal medullary 
solute content. Moreover, saline infusion progressively diluted the urine to a Uosm of 152 
mosm/kg 13 hours after initiating saline therapy, at which time plasma ADH decreased 
from a baseline of 1.9 pg/mL to indeterminate levels. The elimination of the volume 
stimulus for ADH production by saline allowed the coexisting hypo-osmolality to inhibit 
ADH production and induce excretion of dilute urines as serum sodium increased from a 
baseline 120 to 138 mmol/L in the next 48 hours, figure 1. (Maesaka et al, 2007)  
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Interestingly, the baseline FEurate of 29.6% increased further to a peak of 63% and 48% at 
the time of correction of the hyponatremia at 138 mmol/L, figure 2. The effect of saline on 
FEurate has been amply shown to be minimal. This persistently increased FEurate after 
correction of hyponatremia is consistent with RSW and not SIADH, to be discussed later. 
(Maesaka et al, 2007). 
 
Fig. 2. Relationship between serum urate, serum sodium and FEurate during volume 
repletion with saline for 48 hours. Note that persistence of increased FEurate after correction 
of hyponatremia contrasts this to SIADH. Saline has been amply shown to have a meager 
effect on FEurate. (reproduced with permission from publisher)   
In our view, this very instructive case followed predicted physiologic parameters for RSW 
and proved unequivocally the existence of RSW by collectively demonstrating the critical 
decrease in blood volume, increased plasma renin and aldosterone, low normal plasma 
ANP, appropriately increased plasma ADH, which was inhibited by the combination of 
volume repletion and hypo-osmolality, increased free water excretion, and timely correction 
of hyponatremia. These compelling data proved that RSW can occur without evidence of 
clinical cerebral disease and that a low sodium intake will be associated with a low UNa in a 
patient with RSW. (Maesaka et al, 2007)  
7. Emerging value of determining FEurate 
Determination of serum urate in SIADH was first reported in 1971. Patients with SIADH 
had hypouricemia and increased FEurate, which normalized after correction of the 
hyponatremia. (Dorhout Mees et al, 1971) In 1979 Beck duplicated these findings, but 
compared serum urate in SIADH with other causes of hyponatremia. Except for only one 
overlapping value, there was complete separation of serum urate in SIADH from other 
causes of hyponatremia. (Beck, 1979) Correcting the hyponatremia by water restriction was 
accompanied by an increase in serum urate with normalization of a previously increased 
FEurate, figures 3, 4. (Beck, 1979)  Beck concluded that the coexistence of hyponatremia and 
hypouricemia differentiated SIADH from most other causes of hyponatremia. This apparent 
simple method of differentiating SIADH from other causes of hyponatremia stimulated 
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others to investigate this relationship and renal urate handling. Serum urate was 
consistently found to be decreased in SIADH and there was virtually no overlap or partial 
overlap with other causes of hyponatremia. (Assadi & John, 1985; Passamonte 1984;  
Sonnenblick et al, 1988; Sorensen et al, 1988). FEurate was similarly increased in SIADH. 
(Assadi, 1985; Beck, 1979; Bitew, 2009; Decaux, 1990; Dorhout Mees ,1971; Drakakis, 2011; 
Weinberger et al, 1982; Sonnenblick, 1988; Sorenson, 1988)  Several studies also 
demonstrated normalization or reduction of a previously increased FEurate after correction 
of hyponatremia by water restriction, figure 3, 4. (Assadi & John, 1985; Beck, 1979; Decaux et 
al, 1990; DorhoutMees et al, 1971; Drakakis et al, 2011; Sonnenblick et al, 1988) 
Improvements in hypouricemia and increased FEurate after correction of hyponatremia, 
appear to be characteristic findings in SIADH, but the coexistence of hypouricemia and 
hyponatremia has not been found as useful as FEurate, figures 3, 4.  
We encountered 5 patients, in whom an increased FEurate and hypouricemia persisted after 
correction of their hyponatremia by water-restriction, suggesting that these hyponatremic 
patients were pathophysiologically different from SIADH. (Maesaka et al, 1990) The first 
patient had metastatic pancreatic carcinoma with hypoalbuminemia, albumin 1.5 g/dL, 
edema, ascites, hypouricemia (serum urate 1.1 mg/dL), increased FEurate, 34.2%, 
hypophosphatemia, 1.7 mg/dL, with increased FEphosphate, 29.1%, UNa 99mmol/L and 
Uosm 716 mosm/kg. His FEurate remained persistently increased at 30.0% after correction 
of hyponatremia to 138 mmol/L by water-restriction. The edema, ascites and increased 
FEphosphate were inconsistent with SIADH and the collective findings were consistent with 
a variant of the Fanconi syndrome. The second case was a patient with bronchogenic 
carcinoma with a negative CT scan of brain, who presented with serum sodium of 116 
mmol/L, saline-responsive postural hypotension, Uosm 323 mosm/kg, UNa 42 mmol/L, 
serum urate 2.0 mg/dL, FEurate 26.5% and normal renal, adrenal and thyroid function. A 
diagnosis of SIADH was made on the basis of the report by Beck and he was water-
restricted with liberal salt supplementation, which was followed by significant weight loss, 
recurrence of his postural hypotension, weakness, postural dizziness, slurred speech, 
staggered gait and somnolence. His serum sodium finally corrected to 138 mmol/l, and 
FEurate remained elevated at 14.7%, despite being severely volume depleted. At this time, 
his Uosm was 980 mosm/kg, UNa 181 mmol/L and he remained hypouricemic, serum 
urate 2.2 mg/dL. He responded well to saline therapy with reversal of all of his symptoms. 
The increased FEurate and hypouricemia persisted after correction of his hyponatremia by 
water restriction and salt supplementation, suggesting that a persistently elevated FEurate 
and hypouricemia after correction of hyponatremia would be consistent with RSW. We 
found a persistent increase in FEurate and hypouricemia after correction of hyponatremia in 
three additional cases, one with bronchogenic carcinoma that had metastasized to brain, 
another with disseminated Cryptococcus that involved brain and uncomplicated Hodgkins 
disease with no clinical cerebral disease.  All had normal renal adrenal and thyroid function. 
The hyponatremia, high UNa and concentrated urine were consistent with SIADH except 
for the persistent increase in FEurate. The hyponatremia, high UNa and concentrated urine 
were consistent with SIADH except for the persistent increase in FEurate, which was 
construed as being pathophysiologically different from SIADH and might serve to 
differentiate SIADH from RSW, figure 3, 4. Moreover, the absence of clinical cerebral disease 
in 3 of the 5 patients raised questions regarding the appropriateness of the term cerebral salt 
wasting. 
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Fig. 3. Fig. 4. 
Fig. 3. and 4. Relationship between FEurate (FEUA ), serum urate (SUA ) 
and serum sodium (SNa ) before and after correction of hyponatremia in SIADH 
and RSW. Shaded areas represent normal ranges. (Modified from Maesaka, 1999), Figure 3. 
Figure 4 is updated version with elimination of SUA, see test. 
We prospectively evaluated 96 patients with AIDS.  Sixteen patients had combined 
hyponatremia and hypouricemia, 21 were hypouricemic, and 19 of 23 patients studied had 
increased FEurate. Many had increased FEurate with normonatremia, which was consistent 
with RSW and not SIADH. All hyponatremic patients had high UNa and concentrated 
urines that were consistent with SIADH and RSW. Ten hyponatremic patients with saline 
responsive postural hypotension, CVP of 0 cm H2O with high plasma renin and aldosterone 
collectively supported a diagnosis of RSW in AIDS. (Maesaka et al, 1990, 1990)   
We extended our study to neurosurgical patients with diverse etiologies because 12 of 12 
hypouricemia patients with AIDS had cortical atrophy of brain by CT scan. (Maesaka et al, 
1990, 1992) The high incidence of RSW in neurosurgical patients suggested that RSW in 
AIDS might be due to their cerebral disease, so we prospectively studied urate metabolism 
in 29 neurosurgical patients of varying etiologies and 21 age and gender-matched controls. 
Seven patients were hypouricemic, 18 had FEurate > 10% and only 1 patient was 
hyponatremic. (Maesaka et al, 1992)  We postulated that the increase in FEurate without 
hyponatremia was again consistent with RSW that was supported by the volume studies in 
neurosurgical patients. These observations solidified our notion that an increased FEurate 
with normonatremia may be consistent with RSW without a need to correct hyponatremia, 
figures 3, 4. Moreover, an increased FEurate was associated with serum urate > 5 mg/dL, 
suggesting a greater value of FEurate over serum urate. (Maesaka et al, 1992, 1998, 2009) 
A study of urate metabolism focused on other cerebral diseases because patients with AD 
were reported to have lower serum urate. (Kasa et al, 1989) Serum urate was lower and 
FEurate higher in 18 patients with AD as compared to 6 patients with multi infarct dementia 
and 11 age and gender-matched normal controls. (Maesaka et al, 1993)  As in the 
neurosurgical study, only one patient with AD was hyponatremic. The increased FEurate 
with normonatremia suggested that demented patients with AD might have RSW and 
raised the question whether or not an isolated increase in FEurate with normonatremia 
without prior correction of a pre-existing hyponatremia would be consistent with RSW.  
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One drawback to our proposal of determining FEurate after correction of hyponatremia to 
differentiate SIADH from RSW was the unpredictability of correcting the hyponatremia. We 
utilized the recommendation to treat hyponatremic patients with cerebral disease with 
hypertonic saline, regardless of whether or not the patient had SIADH or RSW. (Sterns et al, 
2008) We increased serum sodium to 138 mmol/L within 2-3 days with 1.5% and 
determined FEurate, being aware that saline had only a modest effect on FEurate and would 
not likely alter our results. (Cannon, 1970; Diamond, 1975; Maesaka & Fishbane, 1998; Steele, 
1974) We corrected hyponatremia within 2-3 days in 3 patients, who met usual criteria for 
SIADH, and found a previously increased FEurate to decrease to < 10% in all 3 patients. 
(Drakakis et al, 2011) Normalization of FEurate after correction of hyponatremia can be 
predictably achieved in 2-3 days by hypertonic saline and can be contrasted to a persistent 
increase in FEurate in RSW, figures 3, 4. The rate of correction can be controlled by 
monitoring serum sodium and adjusting free water intake to achieve the desired rate and 
extent of the correction of hyponatremia. These studies confirmed our notion that saline has 
a meager effect on FEurate by decreasing to normal levels during saline infusion. Under the 
proper circumstances of adequate cardiac function, hyponatremia can be corrected with 
1.5% hypertonic saline in a predictably timely fashion to differentiate SIADH from RSW, 
figures 3, 4. (Drakakis et al, 2011)  
7.1 Pathophysiology of increased FEurate in SIADH and RSW  
The mechanisms by which FEurate increases in both SIADH and RSW are presently 
unexplained. The most prominent explanation has been the volume expansion that is seen in 
SIADH, but the saline infusion studies suggest that volume expansion has only a meager 
effect on FEurate. (Cannon et al, 1970; Diamond et al, 1975; Steele et al, 197) The V1 ADH 
receptor has been proposed as a cause for the increase in FEurate in SIADH after 
demonstrating an increase in FEurate by pitressin, and eliminating the effect by a V1-specific 
receptor inhibitor. (Decaux et al, 1996) This explanation is untenable because FEurate 
increased significantly at a time when normal subjects were hyponatremic during intranasal 
dDAVP, which lacks V1 activity, and by normalization of FEurate with correction of 
hyponatremia in SIADH when plasma ADH levels are still elevated. (Boer et al, 1987) It has 
been proposed that the defect in urate transport in SIADH was a result of an inhibition of 
the post secretory reabsorptive site for urate transport, based on the combination of the 
assumed secretory inhibition by pyrazinamide and decrease in post secretory reabsorption 
of urate by sulfapyrazone. (Weinberger et al, 1982) Studies in brush border membranes, 
however, demonstrate increased uptake of urate in the presence of pyrazinamide, 
suggesting that the decrease in urate excretion during pyrazinamide administration was a 
result of increased reabsorption and not inhibition of secretion. (Roch-Ramel et al, 1994) 
Until there is further clarification of the mechanisms and sites at which urate is transported, 
we must conclude that there is increased FEurate at a time when the patient is hyponatremic 
in SIADH, but the mechanism for this unique transport abnormality remains unclear. Lastly, 
the proposal that the chronic hyponatremia or hypo-osmolality contributed to the increase 
in FEurate in SIADH cannot be supported by the normal FEurate that has been reported in 
hyponatremia due to psychogenic polydipsia and more recently, RO, to be discussed below. 
(Ali et al, 2009; Decaux et al, 2000; Imbriano et al, 2011) 
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The increased FEurate in RSW, like that in SIADH, is presently not understood. There is a 
natriuretic factor(s) that is present in plasma and urine of patients with neurosurgical 
diseases and in plasma of patients with AD. As discussed above, this factor(s) has a major 
inhibitory effect on proximal tubule sodium transport. (Maesaka et al, 1993, 1993; Youmans 
& Maesaka, 2011) The proximal tubule is the exclusive site of urate reabsorption and 
predominant site  for phosphate. It would be interesting to speculate that the natriuretic 
factor might have a dose-dependent effect with different affinities for various transporters in 
the proximal tubule. The circulating factor could also explain the persistent increase in 
FEurate after correction of hyponatremia in RSW. Consistent with this speculation is our 
patient with metastatic pancreatic cancer who had transport defects for sodium, urate and 
phosphate that were interpreted as being consistent with the Fanconi syndrome. (Maesaka 
et al, 1990) For the moment, however, there are few insights into mechanisms by which 
FEurate increases in RSW.        
7.2 Hyponatremia with normal FEurate in reset osmostat 
Further appreciation of the emerging importance of determining FEurate in hyponatremic 
patients comes from our study of patients with RO or type C SIADH, which accounts for 
36% of patients with SIADH. (Zerbe et al, 1980)  It is characterized by euvolemia with 
normal renal, adrenal and thyroid function, hyponatremia resulting from ADH stimulation 
at a lower plasma osmolality or a RO, having a reasonably normal diluting and 
concentrating capacity of urine, and maintaining normal sodium balance without correcting 
the hyponatremia. (Wall, 1993) They are typically untreated, but this approach poses a 
therapeutic dilemma because of our tendency to treat most if not all hyponatremics. 
(DeFronzo et al, 1976; Decaux et al, 2009; Elisaf et al, 1990; Hill et al, 1990; Kahn, 2003) We 
encountered 3 patients with hyponatremia and normal FEurate, who were noted to excrete 
urines with Uosm < 200 mosm/kg, that was consistent with RO. Based on these findings, we 
decided to perform water-loading tests in nonedematous hyponatremic patients with 
normal FEurates without a dilute urine in a randomly collected urine, regardless of UNa or 
serum urate. (Imbriano, 2011) In this study of 14 patients, every nonedematous 
hyponatremic patient we encountered with a FEurate of 4-10% had RO as determined by 
Uosm <200 mosm/kg on a random urine collection, 8 patients, or after a normal water-
loading test, 6 patients. As is typical of RO, plasma ADH was undetectable in 4 patients 
studied during the water-loading test. Eleven patients had UNa > 20 mmol/L, 8 were 
hypouricemic, yet all had a normal FEurate of < 10%. Interestingly, 3 patients were on 
losartan and 2 on atorvastatin, which increase urine urate excretion and lower serum urate. 
(Milionis et al, 2004; Yamamoto et al, 2000) These data suggest that chronic hyponatremia 
does not increase FEurate as has been proposed as a contributing factor for the increased 
FEurate in SIADH. (Decaux et al 2000) Comorbid conditions were similar to those reported 
in RO, including 2 patients without comorbidities. These and our other studies refine the 
proposal by Beck, that the coexistence of hyponatremia and hypouricemia differentiates 
SIADH from most other causes of hyponatremia, by stressing the greater value of FEurate 
over serum urate. (Beck, 1979; Maesaka et al, 1998, 2009) We concluded that RO occurs 
commonly, a normal FEurate in a nonedematous hyponatremic patient is highly suggestive 
of RO and FEurate has greater clinical utility than serum urate. (Imbriano et al, 2011) 
FEurate has a physiological basis for its derivation as compared to multiple factors that 
determine serum urate, including endogenous or exogenous purine sources, endogenous 
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production and excretion via gut and urine. Moreover, the arbitrary definition of 
hypouricemia ranging from 1.5-4 mg/dL reflect the uncertainty of the value of serum urate 
as compared to well-defined parameters that have been established for FEurate. (Beck, 1979; 
Maesaka et al, 1990 e; Ramsdell & Kelley, 1973) These studies also introduce the possibility 
that RO is pathophysiologically different from the more traditional SIADH by virtue of the 
normal FEurate and predictability of ADH responses to plasma osmolality.  
8. Change cerebral salt wasting to renal salt wasting 
The 2 cases of RSW without clinical cerebral disease were the impetus to propose replacing 
the designation, cerebral salt wasting, to renal salt wasting. (Bitew et al, 2009; Maesaka et al, 
2007, 2009) Based on these reports, cerebral salt wasting should be considered an outmoded 
and inappropriate designation; it should now be called RSW because RSW will be 
considered in any hyponatremic patient with or without cerebral disease. (Maesaka et al, 
2009) Although we feel that RSW might be rare in patients without clinical cerebral disease, 
these cases of RSW without clinical cerebral disease support our contention that the true 
prevalence of RSW cannot be viewed as rare until future studies can accurately determine 
the prevalence of SIADH and RSW in patients with and without clinical evidence of cerebral 
disease. This would depend on our ability to differentiate SIADH from RSW. The volume 
studies indicate that RSW is much more common than SIADH in neurosurgical patients. We 
hope this expanded approach to hyponatremia and RSW will eliminate the inappropriate 
treatment of RSW by fluid restriction, which has been shown to increase morbidity and 
mortality when misdiagnosed as SIADH. (, Gutierrez & Lin, 2009; Maesaka et al, 1990, 2007; 
Wijdicks et al, 1985) 
9. New approach to hyponatremia and how to differentiate SIADH from RSW 
The evaluation of the patient with hyponatremia traditionally starts with an assessment of 
ECV, whether or not they are euvolemic, hypovolemic or hypervolemic. While this 
approach is fundamentally correct, we are again unable to assess accurately whether the 
patient is euvolemic or hypovolemic, realizing that hypervolemic patients can be identified 
by the presence of edema. We attempted to use UNa to support the volume approach by 
dividing the hypovolemic group into two categories, those with hypovolemia and normal 
kidney function, UNa < 20 mmol/L and those with rSW, UNa > 20 mmol/L. Those with 
euvolemia or mainly SIADH, UNa is usually > 20 mmol/L and hypervolemia, UNa < 20 
mmol/L. The major differential is a UNa of > 20 mmol/L, which reverts back to 
differentiating SIADH from RSW. Differentiating the hypovolemic patient with normal 
renal function from hypervolemic hyponatremics, UNa < 20 mmol/L, is simplified by the 
presence or absence of edema. (Maesaka, 1996) The interpretation of UNa is also 
complicated by many factors, such as diuretics, the acutely vomiting patient with 
bicarbonaturia, acute and chronic kidney diseases and low UNa in the patient with SIADH 
and RSW on a low sodium diet. Limitations of UNa in the evaluation of patients with 
hyponatremia have been noted by others. (Chung et al, 1987) 
Determinations of plasma renin and aldosterone can under proper circumstances contribute 
to differentiating SIADH from RSW. However, many factors can affect one or both values, 
such as the use of diuretics, ACE inhibitors, ARB, NSAIDS, heparin or saline.(Mulatero et al, 
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2002)  Even under ideal circumstances the delay in obtaining these results does not assist us 
on first encounter with the patient.  
It is evident that the evaluation of the volume status or determining UNa has limited utility. 
This dilemma persists to this day on first encounter with the nonedematous hyponatremic 
patient. We developed an algorithm, which emphasizes FEurate in the evaluation of 
hyponatremia, table 1. We propose with supporting data to determine FEurate in any 
nonedematous patient with hyponatremia. If the FEurate is 5-10%, we should consider 
psychogenic polydipsia, RO and prerenal causes, such as congestive heart failure, cirrhosis, 
nephrosis and pre eclampsia, or hypovolemia with normal renal function. Psychogenic 
polydipsia can be eliminated from the history of increased water intake and very dilute 
urines. (Ali et al, 2009) Edematous states can be ruled out by the presence of edema. The 
major obstacle might be the hypovolemic patient with normal renal function and classic 
prerenal azotemia, but the low mean FEurate of 2.85%, possibly high serum urate and UNa 
< 20 mmol/l might assist in differentiating this group from RO. (Steele, 1969) In patients 
who do not fall into the groups mentioned, we would consider RO and search diligently for 
a dilute urine in a random urine collection. In the absence of a dilute random urine, we do 
not recommend performing a water-loading test to prove the diagnosis of RO. (Imbriano et 
al, 2011) We would instead treat them with water restriction and salt supplementation, 
however unsuccessful they are, and consider using ADH receptor inhibitors, vaptans.  
If the FEurate exceeds preferably 12%, there are three possibilities to consider, SIADH, RSW, 
thiazide diuretics and drugs that induce an SIADH-like picture. Thiazide diuretics and 
neurotropics can be readily eliminated by a proper history so the major differential would 
be SIADH and RSW. We propose to correct serum sodium either by water-restriction with 
salt supplementation or 1.5% hypertonic saline and determine FEurate. (Drakakis et al, 2011) 
If FEurate corrects to < 10%, we would proceed with treatment for SIADH or if it exceeds 
10%, preferably >12%, we would treat the patient for RSW with saline. The question 
represented as dotted lines in table 1 depends on whether the coexistence of increased 
FEurate with normonatremia would be diagnostic of RSW. While there are supporting data 
to suggest this to be a valid conclusion, especially in patients with neurosurgical diseases, 
future studies will hopefully provide further insights into this relationship. Because 
neurosurgical patients are routinely treated with hypertonic saline, an increased FEurate 
with normonatremia or hypernatremia would be suggestive of RSW, see above. We have 
found this algorithm to be superior to the previous approach as discussed above and expect 
to make further refinements to this algorithm in the future.  
10. Treatment of the hyponatremic patient with SIADH and RSW 
The increasing reports of significant symptoms being attributed to even mild hyponatremia 
not only shed light on a long unrecognized phenomenon, but introduce the need for some 
urgency in developing adequate treatment strategies for a condition with diverse etiologies 
and divergent therapeutic goals. Treatment, however, has undergone a period of 
uncertainty due to adverse outcomes that are related to delays in treatment and over- 
correction of chronic hyponatremia. (Berl et al, 1990) The approach to methods of correction 
in different clinical conditions will be limited to SIADH and RSW and the reader is referred 
to broader reviews of treating hyponatremia. (Stern et al, 2009; Verbalis et al, 2007) As 
discussed earlier, foremost among the diagnostic and therapeutic dilemma is the need to 
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differentiate SIADH from RSW in order to fulfill divergent therapeutic goals. It is well 
known that severe hyponatremia can cause neurologic symptoms, such as irritability, 
seizures and even apnea, but more subtle alterations in memory and judgment, unsteady 
gait and even falls have been associated with mild hyponatremia that have responded to 
treatment of their hyponatremia. (Berl et al, 2010; Decaux et al, 2006, 2009; Gankam Kengne 
et al, 2008; Renneboog et al, 2006) It is, therefore, pertinent to ask whether “asymptomatic 
hyponatremia exists”. (Schrier, 2010) One of the most alarming outcomes has been the 
descriptions of a four-fold increase in falls that have been attributed to mild hyponatremia, 
mean serum sodium 131 mmol/L, in the elderly. (Renneboog et al, 2006; Gankam Kengne et 
al, 2008) There is, therefore, a movement to consider treating all hyponatremics, including 
the infusion of hypertonic saline to treat hyponatremic patients with brain diseases to avoid 
brain edema regardless of whether or not they have SIADH or RSW. (Sterns & Silver, 2008)    
 
Table 1. New approach to hyponatremia based on FEurate. Normonatremia and FEurate 
without hyponatremia needs further verification, dotted line. 
The standard approach to treating hyponatremia depends on the etiology of the 
hyponatremia. Patients with edematous causes of hyponatremia such as heart failure, 
cirrhosis or nephrosis are treated with a combination of water-restriction, low salt diet, 
diuretics and the ADH inhibitors or vaptans. Vaptans are clearly indicated in edematous 
states and are contraindicated in hypovolemic patients. Of the available vaptans, conivaptan 
inhibits the V1A and V2 receptor for ADH and tolvaptan the V2 receptor. Conivaptan is 
administered only intravenously and inhibits CYP3A4 so its administration must consider 
other agents that might be metabolized by this pathway and potentially increase blood 
levels of conivaptan. (Sterns et al, 2009) Because conivaptan inhibits the V1A receptor, which 
has vasopressive activity, it is not indicated for treatment of hyponatremic cirrhotics. (Sterns 
et al, 2009) SIADH and RO are treated by water-restriction with salt supplementation and 
hypertonic saline in patients with brain disease, but the vaptans appear to be promising for 
both conditions. Vaptans have been shown to increase serum sodium successfully and 
improve symptoms attributed to non hypovolemic hyponatremia, including better 
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symptomatic improvement in patients with SIADH. (Berl et al, 2010; Schrier et al, 2006; 
Verbalis et al, 2011)  Patients should not be water-restricted while being treated with the 
vaptans except under very unusual circumstances to avoid rapid correction of 
hyponatremia.  Serum sodium should be monitored at least within 8 hours of initiating 
vaptan therapy, but we recommend repeating serum sodium determinations earlier if the 
patient increases urine output soon after starting vaptan therapy. (Berl et al, 2010)  The 
increase in urine output suggests that ADH receptor inhibition is occurring rapidly and the 
resulting increase in free water excretion would correct sodium rapidly thereafter, hence a 
recommendation to determine serum sodium at this time. Over-correction of hyponatremia 
can be avoided by closely matching the increased urine volume or if too rapid, by the 
administration of free water and/or intranasal dDAVP.  
The treatment of SIADH, including RO, traditionally starts with the treatment of the 
associated clinical condition, fluid restriction to < 1000 ml/day, salt supplementation, 
occasionally diuretics, demeclocyline and ADH inhibitors. The correction of hyponatremia 
in SIADH by fluid restriction and/or salt supplementation has been slow and often 
incomplete or unsuccessful. Treatment of RO has been generally unsuccessful to the point of 
not recommending any treatment for these patients. The use of vaptans in SIADH can be 
justified by their hypervolemic state, but it is uncertain whether patients with RO are 
similarly volume expanded. Although an increase in volume makes intuitive sense, volume 
studies have not been performed in patients with RO to justify use of vaptans . Our ability to 
identify patients with RO by virtue of a normal FEurate will uncover this common cause of 
hyponatremia and test the efficacy of vaptans in this therapeutically challenging group. 
(Imbriano et al, 2011)  
In contrast to the difficulty of treating patients with SIADH or RO, the treatment of RSW is 
simple. Eliminating the appropriate volume stimulus for ADH secretion in this disorder 
with saline will allow the coexisting hypo-osmolality to inhibit ADH secretion, increase free 
water excretion and correct the hyponatremia.  (Bitew et al, 2009; Maesaka et al, 2007)  Use 
of vaptans is obviously contraindicated in these volume depleted patients. While the 
rationale for increasing salt and water intake in patients with RSW is obvious, we are again 
confronted with our inability to differentiate SIADH from RSW with any degree of certainty. 
This therapeutic dilemma has been partially resolved by the recommendation to treat 
hyponatremic patients with acute neurological/neurosurgical diseases with hypertonic 
saline to prevent the complications associated with brain edema of multiple causes. (Sterns 
& Silver, 2008 and et al, 2009) As discussed earlier, RSW is more common than SIADH in 
neurosurgical diseases and the use of hypertonic saline not only reduces brain edema but 
has other advantages, such as treating their volume depletion. (Sterns & Silver, 2008) 
Administration of hypertonic saline prevents hyponatremia from occurring so an increased 
FEurate would be consistent with RSW. (Youmans & Maesaka, 2011). A timely correction of 
an existing hyponatremia by judicious use of hypertonic saline can also differentiate SIADH 
from RSW, whether FEurate normalizes or remains increased, respectively, figures 3, 4.  
Hyponatremic patients outside of the neurology/neurosurgical ICU, including those with 
nonedematous hyponatremia with or without cerebral disease, need to be evaluated for 
etiology of their hyponatremia, as discussed above. Following the algorithm in table 1 has 
been useful in our hands. Therapy will depend on the etiology of the hyponatremia. In those 
with increased FEurate, the diagnostic dilemma of differentiating SIADH from RSW must 
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be extended to those without clinical cerebral disease. This diagnostic and dependent 
therapeutic dilemma will persist until we have a mindset to consider RSW in these patients 
and develop a better diagnostic approach to solving this dilemma. Recommendations to 
determine FEurate in normonatremic patients have not been resolved except to include it as 
a routine measurement in any patient with acute brain disease and demented patients with 
AD.  
In patients with symptomatic hyponatremia such as muscular irritability, altered mental 
status or seizures, the patient should be treated with hypertonic saline to increase serum 
sodium by 4-6 mmol/l over 4 hours and then slowly thereafter. (Sterns & Silver, 2008) 
Although it is safe to increase serum sodium to normal values in conditions such as in acute 
and documented water intake, marathon runners, that cause acute hyponatremia, we 
recommend gradual improvement in all patients with hyponatremia to avoid any 
contributions rapid correction might add to circumstances in which osmotic demyelination 
might occur irrespective of their sodium, such as in malnourished patients or those with 
liver disease. (Almond et al, 2005, Sterns & Silver, 2008) We favor a conservative approach to 
the correction of chronic hyponatremia by increasing serum sodium <10 mmol/l/24 hrs 
with slower rates for patients with severe malnutrition and cirrhosis to avoid osmotic 
demyelination.  
11. Summary 
The present chapter hopefully provided the following important insights and new 
directions in our understanding of RSW: 
1. an appreciation of the diagnostic and therapeutic dilemma that exists for SIADH and 
RSW.  
2. provided an objective review of how the controversy over the relative prevalence of 
SIADH and RSW evolved.  
3. emphasized our inability to assess accurately the state of ECV as being the root of this 
enigmatic controversy and how the overlapping features of both syndromes make it 
virtually impossible to differentiate SIADH from RSW on first encounter.  
4. reviewed the relative merits by which we determine ECV.  
5. RSW  is much more common than SIADH in neurosurgical patients and RSW can occur 
in the absence of hyponatremia.  
6. although FEurate is increased in both SIADH and RSW, FEurate can differentiate one 
syndrome from the other by reverting to normal in SIADH and being persistently 
increased after correction of hyponatremia.  
7. the demonstration of natriuretic activity in plasma of neurosurgical and in the plasma 
and urine of Alzheimer disease patients with increased FEurate and normonatremia 
introduces the possibility that an increased FEurate with normonatremia might be 
diagnostic of RSW.  
8. the natriuretic factor probably contributes to RSW, has its major effect in the proximal 
tubule where urate is exclusively transported and is not A/BNP.  
9. a normal FEurate in patients with nonedematous hyponatremia is highly suggestive of 
RO and identifies a common and overlooked disorder.  
10. the normal FEurate and predictability of ADH responses suggest that RO might 
represent a group that is pathophysiologically different from SIADH.  
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11. we provide a useful algorithm that utilizes FEurate as central to our approach to 
evaluating patients with hyponatremia.  
12. based on our two cases of renal salt wasting without clinical cerebral disease, we 
propose eliminating the term cerebral salt wasting in favor of renal salt wasting  
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